» Articles » PMID: 35062215

Modeling SARS-CoV-2 Infection in Mice Using Lentiviral HACE2 Vectors Infers Two Modes of Immune Responses to SARS-CoV-2 Infection

Overview
Journal Viruses
Publisher MDPI
Specialty Microbiology
Date 2022 Jan 22
PMID 35062215
Authors
Affiliations
Soon will be listed here.
Abstract

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) caused a severe global pandemic. Mice models are essential to investigate infection pathology, antiviral drugs, and vaccine development. However, wild-type mice lack the human angiotensin-converting enzyme 2 (hACE2) that mediates SARS-CoV-2 entry into human cells and consequently are not susceptible to SARS-CoV-2 infection. hACE2 transgenic mice could provide an efficient COVID-19 model, but are not always readily available, and practically restricted to specific strains. Therefore, there is a dearth of additional mouse models for SARS-CoV-2 infection. We applied lentiviral vectors to generate hACE2 expression in interferon receptor knock-out (IFNAR1) mice. Lenti-hACE2 transduction supported SARS-CoV-2 replication in vivo, simulating mild acute lung disease. Gene expression analysis revealed two modes of immune responses to SARS-CoV-2 infection: one in response to the exposure of mouse lungs to SARS-CoV-2 particles in the absence of productive viral replication, and the second in response to productive SARS-CoV-2 infection. Our results infer that immune response to immunogenic elements on incoming virus or in productively infected cells stimulate diverse immune effectors, even in absence of type I IFN signaling. Our findings should contribute to a better understanding of the immune response triggered by SARS-CoV-2 and to further elucidate COVID-19.

References
1.
Wu M, Nissim L, Stupp D, Pery E, Binder-Nissim A, Weisinger K . A high-throughput screening and computation platform for identifying synthetic promoters with enhanced cell-state specificity (SPECS). Nat Commun. 2019; 10(1):2880. PMC: 6599391. DOI: 10.1038/s41467-019-10912-8. View

2.
Sa Ribero M, Jouvenet N, Dreux M, Nisole S . Interplay between SARS-CoV-2 and the type I interferon response. PLoS Pathog. 2020; 16(7):e1008737. PMC: 7390284. DOI: 10.1371/journal.ppat.1008737. View

3.
Xiong Y, Liu Y, Cao L, Wang D, Guo M, Jiang A . Transcriptomic characteristics of bronchoalveolar lavage fluid and peripheral blood mononuclear cells in COVID-19 patients. Emerg Microbes Infect. 2020; 9(1):761-770. PMC: 7170362. DOI: 10.1080/22221751.2020.1747363. View

4.
Oladunni F, Park J, Pino P, Gonzalez O, Akhter A, Allue-Guardia A . Lethality of SARS-CoV-2 infection in K18 human angiotensin-converting enzyme 2 transgenic mice. Nat Commun. 2020; 11(1):6122. PMC: 7705712. DOI: 10.1038/s41467-020-19891-7. View

5.
Hartman Z, Appledorn D, Amalfitano A . Adenovirus vector induced innate immune responses: impact upon efficacy and toxicity in gene therapy and vaccine applications. Virus Res. 2007; 132(1-2):1-14. PMC: 4039020. DOI: 10.1016/j.virusres.2007.10.005. View